Cargando…

Lactobacillus helveticus SBT2171 Attenuates Experimental Autoimmune Encephalomyelitis in Mice

We recently reported that Lactobacillus helveticus SBT2171 (LH2171) inhibited the proliferation and inflammatory cytokine production of primary immune cells in vitro, and alleviated collagen-induced arthritis (CIA) in mice, a model of human rheumatoid arthritis (RA). In this study, we newly investig...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamashita, Maya, Ukibe, Ken, Matsubara, Yumi, Hosoya, Tomohiro, Sakai, Fumihiko, Kon, Shigeyuki, Arima, Yasunobu, Murakami, Masaaki, Nakagawa, Hisako, Miyazaki, Tadaaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5786557/
https://www.ncbi.nlm.nih.gov/pubmed/29403442
http://dx.doi.org/10.3389/fmicb.2017.02596
_version_ 1783295801042141184
author Yamashita, Maya
Ukibe, Ken
Matsubara, Yumi
Hosoya, Tomohiro
Sakai, Fumihiko
Kon, Shigeyuki
Arima, Yasunobu
Murakami, Masaaki
Nakagawa, Hisako
Miyazaki, Tadaaki
author_facet Yamashita, Maya
Ukibe, Ken
Matsubara, Yumi
Hosoya, Tomohiro
Sakai, Fumihiko
Kon, Shigeyuki
Arima, Yasunobu
Murakami, Masaaki
Nakagawa, Hisako
Miyazaki, Tadaaki
author_sort Yamashita, Maya
collection PubMed
description We recently reported that Lactobacillus helveticus SBT2171 (LH2171) inhibited the proliferation and inflammatory cytokine production of primary immune cells in vitro, and alleviated collagen-induced arthritis (CIA) in mice, a model of human rheumatoid arthritis (RA). In this study, we newly investigated whether LH2171 could relieve the severity of experimental autoimmune encephalomyelitis (EAE), a murine model of multiple sclerosis (MS), which is an autoimmune disease, but develop the symptoms by different mechanisms from RA. In MS and EAE, main cause of the disease is the abnormality in CD4(+) T cell immunity, whereas in RA and CIA, is that in antibody-mediated immunity. The intraperitoneal administration of LH2171 significantly decreased the incidence and clinical score of EAE in mice. LH2171 also reduced the numbers of pathogenic immune cells, especially Th17 cells, in the spinal cord at the peak stage of disease severity. Interestingly, before the onset of EAE, LH2171 administration remarkably decreased the ratio of Th17 cells to CD4(+) T cells in the inguinal lymph nodes (LNs), where pathogenic immune cells are activated to infiltrate the central nervous system, including the spinal cord. Furthermore, the expression of interleukin (IL)-6, an inflammatory cytokine essential for Th17 differentiation, decreased in the LNs of LH2171-administered mice. Moreover, LH2171 significantly inhibited IL-6 production in vitro from both DC2.4 and RAW264.7 cells, model cell lines of antigen-presenting cells. These findings suggest that LH2171 might down-regulate IL-6 production and the subsequent Th17 differentiation and spinal cord infiltration, consequently alleviating EAE symptoms.
format Online
Article
Text
id pubmed-5786557
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-57865572018-02-05 Lactobacillus helveticus SBT2171 Attenuates Experimental Autoimmune Encephalomyelitis in Mice Yamashita, Maya Ukibe, Ken Matsubara, Yumi Hosoya, Tomohiro Sakai, Fumihiko Kon, Shigeyuki Arima, Yasunobu Murakami, Masaaki Nakagawa, Hisako Miyazaki, Tadaaki Front Microbiol Microbiology We recently reported that Lactobacillus helveticus SBT2171 (LH2171) inhibited the proliferation and inflammatory cytokine production of primary immune cells in vitro, and alleviated collagen-induced arthritis (CIA) in mice, a model of human rheumatoid arthritis (RA). In this study, we newly investigated whether LH2171 could relieve the severity of experimental autoimmune encephalomyelitis (EAE), a murine model of multiple sclerosis (MS), which is an autoimmune disease, but develop the symptoms by different mechanisms from RA. In MS and EAE, main cause of the disease is the abnormality in CD4(+) T cell immunity, whereas in RA and CIA, is that in antibody-mediated immunity. The intraperitoneal administration of LH2171 significantly decreased the incidence and clinical score of EAE in mice. LH2171 also reduced the numbers of pathogenic immune cells, especially Th17 cells, in the spinal cord at the peak stage of disease severity. Interestingly, before the onset of EAE, LH2171 administration remarkably decreased the ratio of Th17 cells to CD4(+) T cells in the inguinal lymph nodes (LNs), where pathogenic immune cells are activated to infiltrate the central nervous system, including the spinal cord. Furthermore, the expression of interleukin (IL)-6, an inflammatory cytokine essential for Th17 differentiation, decreased in the LNs of LH2171-administered mice. Moreover, LH2171 significantly inhibited IL-6 production in vitro from both DC2.4 and RAW264.7 cells, model cell lines of antigen-presenting cells. These findings suggest that LH2171 might down-regulate IL-6 production and the subsequent Th17 differentiation and spinal cord infiltration, consequently alleviating EAE symptoms. Frontiers Media S.A. 2018-01-22 /pmc/articles/PMC5786557/ /pubmed/29403442 http://dx.doi.org/10.3389/fmicb.2017.02596 Text en Copyright © 2018 Yamashita, Ukibe, Matsubara, Hosoya, Sakai, Kon, Arima, Murakami, Nakagawa and Miyazaki. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Microbiology
Yamashita, Maya
Ukibe, Ken
Matsubara, Yumi
Hosoya, Tomohiro
Sakai, Fumihiko
Kon, Shigeyuki
Arima, Yasunobu
Murakami, Masaaki
Nakagawa, Hisako
Miyazaki, Tadaaki
Lactobacillus helveticus SBT2171 Attenuates Experimental Autoimmune Encephalomyelitis in Mice
title Lactobacillus helveticus SBT2171 Attenuates Experimental Autoimmune Encephalomyelitis in Mice
title_full Lactobacillus helveticus SBT2171 Attenuates Experimental Autoimmune Encephalomyelitis in Mice
title_fullStr Lactobacillus helveticus SBT2171 Attenuates Experimental Autoimmune Encephalomyelitis in Mice
title_full_unstemmed Lactobacillus helveticus SBT2171 Attenuates Experimental Autoimmune Encephalomyelitis in Mice
title_short Lactobacillus helveticus SBT2171 Attenuates Experimental Autoimmune Encephalomyelitis in Mice
title_sort lactobacillus helveticus sbt2171 attenuates experimental autoimmune encephalomyelitis in mice
topic Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5786557/
https://www.ncbi.nlm.nih.gov/pubmed/29403442
http://dx.doi.org/10.3389/fmicb.2017.02596
work_keys_str_mv AT yamashitamaya lactobacillushelveticussbt2171attenuatesexperimentalautoimmuneencephalomyelitisinmice
AT ukibeken lactobacillushelveticussbt2171attenuatesexperimentalautoimmuneencephalomyelitisinmice
AT matsubarayumi lactobacillushelveticussbt2171attenuatesexperimentalautoimmuneencephalomyelitisinmice
AT hosoyatomohiro lactobacillushelveticussbt2171attenuatesexperimentalautoimmuneencephalomyelitisinmice
AT sakaifumihiko lactobacillushelveticussbt2171attenuatesexperimentalautoimmuneencephalomyelitisinmice
AT konshigeyuki lactobacillushelveticussbt2171attenuatesexperimentalautoimmuneencephalomyelitisinmice
AT arimayasunobu lactobacillushelveticussbt2171attenuatesexperimentalautoimmuneencephalomyelitisinmice
AT murakamimasaaki lactobacillushelveticussbt2171attenuatesexperimentalautoimmuneencephalomyelitisinmice
AT nakagawahisako lactobacillushelveticussbt2171attenuatesexperimentalautoimmuneencephalomyelitisinmice
AT miyazakitadaaki lactobacillushelveticussbt2171attenuatesexperimentalautoimmuneencephalomyelitisinmice